Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 What are the real lessons from Vioxx?

Literature DB >> 16048352

What are the real lessons from Vioxx?

I Ralph Edwards.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2005 PMID： 16048352 DOI： 10.2165/00002018-200528080-00001

Source DB: PubMed Journal: Drug Saf ISSN： 0114-5916 Impact factor: 5.606

× No keyword cloud information.

11 in total

1. Risk management of marketed drugs: FDA and the interface with the practice of medicine.

Authors: K Uhl; P Honig
Journal: Pharmacoepidemiol Drug Saf Date: 2001-05 Impact factor: 2.890

2. Labelling and 'Dear Doctor' letters: are they noncommittal?

Authors: A C Kees van Grootheest; I Ralph Edwards
Journal: Drug Saf Date: 2002 Impact factor: 5.606

3. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.

Authors: Wayne A Ray; C Michael Stein; James R Daugherty; Kathi Hall; Patrick G Arbogast; Marie R Griffin
Journal: Lancet Date: 2002-10-05 Impact factor: 79.321

4. Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of National pharmacovigilance Centres.

Authors: Malin Ståhl; I Ralph Edwards; Geoffrey Bowring; Anne Kiuru; Marie Lindquist
Journal: Drug Saf Date: 2003 Impact factor: 5.606

5. Agencies "failed miserably" over COX-2 inhibitor.

Authors: Barbara Kermode-Scott
Journal: BMJ Date: 2005-01-15

6. Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database.

Authors: B E Wiholm
Journal: Curr Med Res Opin Date: 2001 Impact factor: 2.580

Review 7. An evidence-based evaluation of the gastrointestinal safety of coxibs.

Authors: Claire Bombardier
Journal: Am J Cardiol Date: 2002-03-21 Impact factor: 2.778

8. Dextropropoxyphene.

Authors: I R Edwards
Journal: N Z Med J Date: 1985-03-27

9. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

Authors: Peter Jüni; Linda Nartey; Stephan Reichenbach; Rebekka Sterchi; Paul A Dieppe; Matthias Egger
Journal: Lancet Date: 2004 Dec 4-10 Impact factor: 79.321

10. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.

Authors: S Z Zhao; M W Reynolds; J Lejkowith; A Whelton; F M Arellano
Journal: Clin Ther Date: 2001-09 Impact factor: 3.393

8 in total

Review 6. Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?

Authors: Preciosa M Coloma; Gianluca Trifirò; Vaishali Patadia; Miriam Sturkenboom
Journal: Drug Saf Date: 2013-03 Impact factor: 5.606

7. Pharmacovigilance for a revolving world: prospects of patient-generated data on the internet.

Authors: G Niklas Norén
Journal: Drug Saf Date: 2014-10 Impact factor: 5.606

8. Causality Assessment in Pharmacovigilance: Still a Challenge.

Authors: I Ralph Edwards
Journal: Drug Saf Date: 2017-05 Impact factor: 5.606